Abstract
Before results of phase III trials leading to FDA approval of docetaxel for castrate-progressive prostate cancer were published (N Engl J Med 2004; 351:1502 and N Engl J Med 2004; 351:1513), various treatments were used to manage the disease. These included conventional androgen-deprivation therapy (ADT) as well as a popular regimen consisting of ketoconazole and doxorubicin alternating weekly with vinblastine and estramustine (KA/VE). To test whether the addition of KA/VE …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
